The Lancet Psychiatry, Год журнала: 2024, Номер unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Psychiatry Research, Год журнала: 2025, Номер 345, С. 116359 - 116359
Опубликована: Янв. 11, 2025
Язык: Английский
Процитировано
3
American Journal of Psychiatry, Год журнала: 2025, Номер 182(1), С. 21 - 32
Опубликована: Янв. 1, 2025
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain are effective safe treatment of major depressive disorder, treatment-resistant depression, posttraumatic stress disorder. Preliminary evidence also supports efficacy other disorders (e.g., tobacco alcohol use disorders). Notwithstanding promise psychedelics, concerns have arisen with respect to interpretability translatability study results. For example, aspects related short- long-term safety, abuse liability, essentiality psychedelic "trip" psychological support are, inter alia, insufficiently characterized agents. The overarching aims this overview 1) review methodological affect inferences interpretation extant studies disorders, 2) provide guidance future development psychiatry, critical clinical implementation.
Язык: Английский
Процитировано
2
Frontiers in Neuroscience, Год журнала: 2024, Номер 18
Опубликована: Июль 10, 2024
Alzheimer’s disease (AD) stands as a formidable neurodegenerative ailment and prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency innovative treatment modalities. Psilocybin, psychoactive alkaloid intrinsic hallucinogenic mushrooms, has garnered attention within neuropsychiatric realm due its established safety efficacy in treating depression. Nonetheless, potential therapeutic avenue remains largely uncharted. This comprehensive review endeavors encapsulate pharmacological effects psilocybin while elucidating existing evidence concerning mechanisms contributing positive impact on AD. Specifically, active metabolite psilocybin, psilocin, elicits through modulation 5-hydroxytryptamine 2A receptor (5-HT2A receptor). causes heightened neural plasticity, diminished inflammation, improvements cognitive functions such creativity, flexibility, emotional facial recognition. Noteworthy is psilocybin’s promising role mitigating anxiety depression symptoms patients. Acknowledging attendant adverse reactions, we proffer strategies aimed at tempering or effects. Moreover, broach ethical legal dimensions inherent exploration treatment. By traversing these avenues, We propose nuanced management disease.
Язык: Английский
Процитировано
7
Journal of Parkinson s Disease, Год журнала: 2025, Номер unknown
Опубликована: Фев. 2, 2025
Background Psychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance acceptance has been reported following psilocybin administration with Objective To report for the first time effect of a patient. Methods non-depressed 43-year-old female 2-year history presented difficulty PD, anxious ruminations and pessimism. The patient declined an increase dopaminergic medication or introduction anxiolytic. Therapeutic education was not beneficial. received four sessions high-dose PAP within one year. Neurological psychiatric assessments were performed before at year follow-up using qualitative interviews quantitative assessment motor status, dispositional optimism, depression, anxiety, apathy, well-being. Results well tolerated. It significantly improved patient's overall pessimistic outlook on her future decreased worries about potential handicap due PD. Her general well-being improved, as all psychometric scores except apathy scale. Motor status remained unchanged. Better allowed accept pharmacological treatment adjustment. Conclusions could be safe useful pessimism difficulties accepting by promoting profound decentration habitual thoughts emotions, improving mood acceptance. Randomized, controlled studies are needed confirm this result.
Язык: Английский
Процитировано
0
Current Addiction Reports, Год журнала: 2025, Номер 12(1)
Опубликована: Фев. 19, 2025
Язык: Английский
Процитировано
0
Biological Psychiatry, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap research on bipolar depression. While several antipsychotics been investigated for their efficacy due to the reduced risk mania induction, RAADs, such as (es)ketamine, scarce despite demonstrated safety and effectiveness. This review gives an overview current developments RAADs context disorder. Both published studies well phase II, III IV (based clinicaltrials.gov) are reviewed this work. The following RAAD substance classes or currently possible treatments depression: NMDA antagonists indirect AMPA agonists (ketamine, esketamine, riluzole, felbamate), GABA-A activators positive allosteric modulators (zuranolone, pregnenolone, PEA), psychedelics (psilocybin, 5-MeO-DMT), muscarine receptor (scopolamine), kappa-opioid (navacaprant). Other than well-established (es)ketamine treating depression, has little effort treatment Recent into demonstrates growing field mechanisms action pharmacological However, is urgent need well-controlled clinical expand options improve outcomes millions affected individuals worldwide.
Язык: Английский
Процитировано
0
Dialogues in Clinical Neuroscience, Год журнала: 2025, Номер 27(1), С. 1 - 12
Опубликована: Март 19, 2025
The increasing prevalence of dementia within an ageing global population, combined with prolonged life expectancy, accentuates Alzheimer's disease (AD) as a multifaceted healthcare challenge. This challenge is further compounded by the limited therapeutic options currently available. Addressing intricacies AD management, mitigation comorbidities has emerged pivotal facet treatment. Comorbid conditions, such neurobehavioral symptoms, play role in shaping clinical course, and outcomes this pathology; highlighting importance comprehensive care approaches for affected individuals. Exploration psychedelic compounds psychiatric palliative settings recently uncovered promising potential, enhancing neuroplasticity, emotional processing connection. These effects are particularly relevant context AD, where therapy offers hope not only mitigating core symptoms but also addressing array associated condition. integration method chance to significantly enhance provided those navigating intricate landscape AD. Therefore, current paper reviews link between more frequent additional health conditions that may coexist dementia, explores potential these concurrent conditions.
Язык: Английский
Процитировано
0
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер unknown, С. 111243 - 111243
Опубликована: Янв. 1, 2025
Chronic stress exerts profound effects on mental health, contributing to disorders such as depression, anxiety, and cognitive impairment. This study examines the potential of psilocybin alleviate behavioral despair deficits in a rodent model chronic stress, focusing interplay between Hypothalamic-Pituitary-Adrenal (HPA) axis Endocannabinoid System (ECS). Twenty-two male Wistar rats were divided into control groups. Animals within group exposed predator odor social instability induce either sham treated, or given psilocybin. Behavioral assessments conducted using Open Field Test, Sucrose Preference Novel Object Recognition, Elevated Plus Maze, Forced Swimming Test evaluate locomotion, anhedonia, memory, despair, respectively. Blood brain samples analyzed for biochemical markers. Results indicated that significantly reduced stress-induced impairments, likely through ECS-mediated downregulation HPA axis. These findings suggest early intervention with has sustained beneficial stress-related disturbances, underscoring its novel therapeutic approach health disorders.
Язык: Английский
Процитировано
0
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер unknown, С. 111249 - 111249
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер unknown, С. 111279 - 111279
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0